Home  |  About us  |  Editorial board  |  Ahead of print  | Current issue  |  Archives  |  Submit article  |  Instructions |  Search  |   Subscribe  |  Advertise  |  Contacts  |  Login 
  Users Online: 797Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
REVIEW ARTICLE

Consent concerns in clinical trials of investigational therapies for COVID-19: Vulnerability versus voluntariness


 Consultant – Clinical Research and Drug Development, Mumbai, Maharashtra, India

Correspondence Address:
Arun Bhatt,
303-4, Dheeraj Valley 3/C, Mohan Gokhale Road, Goregaon East, Mumbai - 400 063, Maharashtra
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/picr.PICR_271_20

Obtaining informed consent from vulnerable patients participating in clinical trials of investigational therapies for COVID-19 is a major ethical challenge. Ethical and operational considerations – voluntariness, waiver, timing, time, documentation, and responsibilities of the sponsor, the investigator, and the ethics committee – are discussed briefly.
    
 

  Search Pubmed for
 
    -  Bhatt A
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed37    
    PDF Downloaded1    

Recommend this journal